Praxis precision medicines provides corporate update and reports first quarter 2025 financial results

On track for six major study readouts across four programs over the next 12 months ready to initiate pivotal studies in two developmental and epileptic encephalopathy (dee) programs in mid-year 2025: emerald for broad dees with relutrigine and embrave3 for scn2a gof with elsunersen vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability praxis to host a virtual investor event on friday, may 2, 2025 to discuss its dee portfolio [registration link] cash and investments of $472 million as of march 31, 2025, maintains runway into 2028 boston, may 02, 2025 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2025. “we have made substantial progress in advancing our promising late-stage epilepsy portfolio and are firing on all cylinders through this unpredictable time in the industry,” said marcio souza, president and chief executive officer of praxis.
PRAX Ratings Summary
PRAX Quant Ranking